Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jun Gong MD

Jun Gong MD

Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California

Jun Gong, MD, is an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Cedars-Sinai Medical Center. As a medical oncologist, his primary clinical interests are in gastrointestinal (GI), hepatobiliary, and genitourinary (GU) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, radiology, and urology. Dr. Gong is focused on translational and clinical cancer research with interests in early therapeutic trials (immunotherapy, targeted therapies, biologics, and other systemic therapies) and biomarker development to improve patient outcomes in GI and GU cancers. 

Disclosures

Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas, Amgen, Pfizer, Seagen, and Bayer.

Recent Contributions to PracticeUpdate:

  1. Second-Line Tyrosine Kinase Inhibitor Therapy After Combination Immunotherapy for Patients With Renal Cell Carcinoma
  2. Deferred Cytoreductive Nephrectomy Following Presurgical VEGFR-Targeted Therapy for Primary Metastatic ccRCC
  3. FDG-PET/CT Improves Detection and Monitoring of Bone Metastases in Patients With Advanced RCC
  4. Increased Survival Benefit of Immunotherapy-Based Combinations for Metastatic ccRCC
  5. Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients With Clear Cell mRCC
  6. Racial and Ethnic Differences in Survival in Contemporary mRCC Patients According to Alternative Treatment Modalities
  7. Lenvatinib Plus Pembrolizumab in Patients With Advanced RCC, Endometrial Cancer, and Other Advanced Solid Tumors
  8. Combined Bevacizumab/Avastin and Erlotinib/Tarceva for the Treatment of Metastatic Renal Cell Carcinoma
  9. ASCO GU 2020: Abstract Recommendations From Dr. Jun Gong
  10. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma

Elsewhere

Recently Updated